¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple puncture method"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • compensation method
    º¸»ó¹ý
  • convergent method
    ¼ö·ÅÁ¶»ç¹ý
  • cough plate method
    ±âħÆòÆÇ¹ý
  • cup cylinder method
    ¿øÅë¹ý
  • chain termination method
    »ç½½Á¾·á¹ý, ¿¬¼âÁ¾·á¹ý
  • checkerboard method
    ¹ÙµÏÆÇ¹æ¹ý
  • dye dilution method
    »ö¼ÒÈñ¼®¹ý
  • dilution egg counting method
    Èñ¼®Ãæ¶õ°è»ê¹ý
  • disc method
    ¿ø¹Ý¹ý, ¿ø¹ÝÈ®»ê¹ý
  • distribution-free method
    ºñºÐÆ÷¹æ¹ý
  • double blind method
    ÀÌÁ߸Ͱ˹ý, °ã´«°¡¸²¹ý
  • double investing method
    ÀÌÁ߸Ÿô¹ý
  • exact method
    Á÷Á¢È®·ü¹ý
  • exclusion method
    ¹èÁ¦¹æ¹ý
  • expansion method
    ÆØÃ¢¹æ¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • bisecting method
    À̵îºÐ¸é¹ý
  • black method
    ºí·¢¹æ¹ý
  • bolus-tracking method
    µ¢¾î¸®ÃßÀû¹æ¹ý
  • brine flotation method
    ½Ä¿°¼öºÎÀ¯¹ý
  • candle jar method
    ÃкҺ´¹è¾ç¹ý
  • capillary tube method
    ¸ð¼¼½ÃÇè°ü¹ý
  • cava pocket method
    ´ëÁ¤¸ÆÆ÷ÄϹý
  • chain termination method
    ¿¬¼âÁ¾·á¹ý
  • checkerboard method
    ¹ÙµÏÆÇ¹æ¹ý
  • closed dressing method
    Æó¼âºØ´ë¹ý
  • column diffusion method
    ±âµÕÈ®»ê¹æ¹ý
  • comparative method
    ºñ±³¹ý
  • compensation method
    º¸»ó¹ý
  • convergent method
    ¼ö·ÅÁ¶»ç¹ý
  • cough plate method
    ±âħÆòÆÇ¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • gradient method
    °è´ÜÀû°Ë»ç¹ý
  • graphic method
    ±×·¡ÇÁ¹ý, ¼±µµ¹ý(ËÛËÀËÑ).
  • gravimetric method
    Áß·®¹ý(ñìÕáÛö).
  • hanging drop method
    ÇöÀû¹ý(úØîÙÛö).
  • hemiglobincyanide <= cyanmethemoglobin> method
    ½Ã¾ÈÇì¹Ì±Û·Îºó¹ý<½Ã¾È¸ÞÆ®Çì¸ð±Û·Îºó¹ý>
  • high flow method
    °íÀ¯·®¹ý(ÍÔêüåÖÛö).
  • homozygous typing method
    µ¿ÇüÁ¢ÇÕ¼º Çüº°ÆÇº°¹ý
  • hypobromite method
    ÇÏÀÌÆ÷ºê·Ò»ê¿°¹ý.
  • illumination method
    Á¶¸í¹ý(Ì¡ËÎËÑ).
  • immersion method
    ¼öħ¹ü (â©öÙÛö)
  • immunodiagnostic method
    ¸é¿ªÁø´Ü(¹æ)¹ý
  • impression method
    Àλó¹ý(ìÔßÚÛö).
  • incision method
    Àý°³¹ý(ü°³¹ý).
  • indicator dilution method
    Áö½Ã¾àÈñ¼®¹ý.
  • indirect direct method
    °£Á¢Á÷Á¢¹ý(ÊàïÈòÁ ïÈÛö).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • multiple characters
  • multiple compressed tablet
    ´ÙÁß¾ÐÃàÁ¤Á¦(Òýñìäâõêïüð¥).
  • multiple congenital polyposis
    ´Ù¹ß¼º ¼±Ãµ¼º(¡­à»ô¸àõ) Æú¸³Áõ(¡­ñø)
  • multiple convulsive tic
    ´Ù¹ß¼º °æ·Ã¼º(ÒýÛ¡ àõÌâÕýàõ) ƽ.
  • multiple correlation
    Áß»ó°ü( Ì¡Ë×Ë´).
  • multiple cranial nerve palsy
    ´Ù¹ß¼º ³ú½Å°æ¸¶ºñ(ÒýÛ¡àõÒàãêÌè Ýö).
  • multiple cylindroma
    ´Ù¹ß¼º ¿øÁÖÁ¾
  • multiple deformity
    º¹ÇÕ±âÇü
  • multiple division
    º¹ºÐ¿­(ÜÜÝÂæñ).
  • multiple drug resistance
    ´ÙÁ¦³»¼º
  • multiple drug resistance gene
    º¹ÇÕ¾àÁ¦³»¼ºÀ¯ÀüÀÚ
  • multiple dysplasia (lipochondrodysplasia)
    ¹µÇü¼ºÀå¾Ö (Áö¹æ¿¬°ñÇü¼ºÀå¾Ö)
  • multiple echo
    ´ÙÁß ¿¡ÄÚ
  • multiple echo
    ´ÙÁß (Òýñë) ¿¡ÄÚ
  • multiple embolism
    ¹æ»ç ´Ù¹ß¼º »öÀüÁõ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Sanger-Coulson method
    »ý°Å-Äð¼Õ ¹ý(Ûö)
  • Sevag method
    ¼¼¹Ù±×¹ý(Ûö)
  • Somogyi-Nelson method
    ¼Ò¸ðÁö-.³Ú½¼¹ý(Ûö)
  • two out of three method
    »ïÁß ÅÃÀ̹ý(ß²ñé÷Éì£Ûö)
  • van Slyke method
    ¹Ý ½½¶óÀÌÅ©¹ý(Ûö)
  • Warburg method
    ¹Ù¸£ºÎ¸£Å©¹ý(Ûö)
  • Warburg's direct method
    ¹Ù¸£ºÎ¸£Å© Á÷Á¢¹ý(òÁïÈÛö)
  • Wilzbach method
    ºôÂê¹ÙÈå ¹ý(Ûö)
  • Wolfson's method
    ¿ïÇÁ½¼ ¹ý(Ûö)
  • Zimmerman method
    Áü¸Ó¸¸¹ý(Ûö)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
ERM electrochemical relaxation method; extended radical mastectomy
FDTD finite difference time domain [method]
FEM female; femur, femoral; finite element method
HAREM heparin assay rapid easy method
HARM heparin assay rapid method
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
MCS Multiple Chemical Sensitivities
MCS Multiple Chemical Sensitivity
MCQ multiple choice question
MCA Multiple Classification Analysis
MDR Multiple Drug Resistance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • double investing method
    ÀÌÁß ¸Å¸ô¹ý
  • draining method
    ¹è³ó¹ý, È긮´Â ¹æ¹ý
    »óó, ±Ë¾ç, °øµ¿¿¡¼­ ¾×ü³ª ¹è¼³¹°À» ü°èÀûÀ¸·Î ¹èÃâ½ÃŰ´Â °Í.
  • dye dilution method
    »ö¼Ò Èñ¼®¹ý
  • electromyogram biofeedback method
    ±ÙÀüµµ ¹ÙÀÌ¿ÀÇǵå¹é¹ý
    ¹ÙÀÌ¿ÀÆÐµå¹éÀÇ ÁöÇ¥·Î ±ÙÀüµµ¸¦ »ç¿ëÇÏ´Â °ÍÀÌ°í ±Ù·Â Áõ°­ ÈÆ·Ã°ú ±Ù ÀÌ¿Ï ÈÆ·Ã°ú´Â ÀüÇô ¹Ý´ëÀÇ Ä¡·á¹ýÀ¸·Î ÇÔ²² ÀÌ¿ëµÈ´Ù. ±Ù·Â Áõ°­ ÈÆ·ÃÀ¸·Î¼­´Â ¸»ÃÊ½Å°æ ¸¶ºñ, ³úÁ¹Áß, ³ú¼º ¸¶ºñ µî¿¡ »ç¿ëµÇ°í ±ÙÀÌ¿Ï ÈÆ·ÃÀ¸·Î¼­´Â »ç°æ µî¿¡ »ç¿ëµÈ´Ù.
  • expansion method
    ÆØÃ¢ ¹æ¹ý
    ¸Å¸ôÀçÀÇ °æÈ­ ÆØÃ¢, °¡¿­ ÆØÃ¢À» ÀÌ¿ëÇϰųª ¸ðÇü Àç·áÀÇ °æÈ­ ÆØÃ¢À» ÀÌ¿ëÇÏ´Â ¹æ¹ýÀÌ´Ù.
  • fast gradient recalled echo method
    °í¼Ó °æ»ç ȸº¹ ¿¡ÄÚ ±â¹ý
  • flash method
    ¿ìÀ¯ ¼Òµ¶¹ý
    ¿ìÀ¯¸¦ 80¡É±îÁö ±Þ¼ÓÈ÷ °¡¿­ÇÑ ÈÄ¿¡ ±Þ¼ÓÈ÷ 5¡É·Î ³»¸®´Â ¸ê±Õ¹ý.
  • functional jaw orthopedic method
    ±â´ÉÀû ¾Ç±³Á¤¹ý
  • immunofluorescence method
    ¸é¿ª Çü±¤¹ý
    Ç×ü³ª Ç׿ø¿¡ Ç÷ç¿À·¹¼¼ÀÎÀ̳ª ·Î´Ù¹Î°ú °°Àº Çü±¤ »ö¼Ò¸¦ Ç¥ÁöÇÑ °ÍÀ» »ç¿ëÇÏ¿© ü¾×°ú Á¶Á÷ µî¿¡ Á¸ÀçÇÏ´Â Ç׿ø ¶Ç´Â Ç×ü¸¦ °ËÃâÇÏ´Â ¹æ¹ý. Ç×ü¸¦ Ç¥ÁöÇÏ´Â °æ¿ì¿¡´Â ´ë°³ Çü±¤ Ç×ü¹ýÀ̶ó°í ºÎ¸¥´Ù. Á÷Á¢¹ý°ú °£Á¢¹ýÀÇ 2°¡Áö ¹æ¹ýÀÌ Àִµ¥, Çü±¤ Ç×üÀÇ °æ¿ì¸¦ ¸»Çϸé Á÷Á¢¹ýÀº Á¶Á÷ ¼Ó¿¡ Á¸ÀçÇÏ´Â Ç׿ø¿¡ ´ëÇÏ¿© ƯÀÌÇÏ°Ô °áÇÕÇÏ´Â Çü±¤ Ç¥Áö Ç×ü¸¦ ¾ãÀº Á¶Á÷ ÀýÆí¿¡ ¹ÝÀÀ½Ã۰í, ±× ÀýÆíÀ» Àß ¾Ä¾î¼­ Çü±¤Çö¹Ì°æÀ¸·Î °üÂûÇϸé Á¶Á÷ ¼ÓÀÇ Ç׿ø°ú °áÇÕÇÑ Çü±¤ Ç×ü°¡ Çü±¤À» ¹ßÇϹǷΠ±× Ç׿øÀÇ Á¸À縦 ¾Ë ¼ö ÀÖ´Ù. °£Á¢¹ýÀº ¸ÕÀú Á¶Á÷ ÀýÆí ¼ÓÀÇ Ç׿ø°ú ÀÌ¿¡ ´ëÀÀÇÏ´Â ¹«Ç¥Áö Ç×ü¸¦ ¹ÝÀÀ½ÃŲ ÈÄ¿¡ ¾Ä°í, ¹«Ç¥Áö Ç×ü¿Í ƯÀÌÇÏ°Ô ¹ÝÀÀÇϴ ǥÁö Ç×ü¸¦ ¹ÝÀÀ½ÃÄѼ­ ¾ÄÀº ´ÙÀ½ Çü±¤Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© Ç׿øÀÇ Á¸À縦 °£Á¢ÀûÀ¸·Î °ËÃâÇÏ´Â ¹æ¹ýÀ¸·Î¼­ Á÷Á¢¹ý¿¡ ºñÇØ Çü±¤·®ÀÌ Áõ´ëÇϹǷΠ°ËÃâ¿¡ ¿ëÀÌÇÏ´Ù.
  • indirect method
    °£Á¢¹ý
    䵿ÇÑ Àλ󿡼­ Á¦ÀÛµÈ ¸ðÇü»ó¿¡¼­ Ä¡°ü ¼öº¹¹°À» Á¦ÀÛÇÏ´Â ¹æ¹ý.
  • indirect-direct method inlay
    Á÷Á¢ °£Á¢¹ý Àη¹ÀÌ
    Á÷Á¢¹ý°ú °£Á¢¹ýÀ» º´¿ëÇÏ¿© ¸¸µç Àη¹ÀÌ.
  • injection molding method
    »çÃâ ¼ºÇü¹ý
  • Kaiserling's method
    Ä«ÀÌÁ¦¸¦¸µ ÀúÀå¹ý
    Ç¥º»À» Æ÷¸£¸»¸° 40cc, ¹° 2,000cc, Áú»êÄ®·ý 30g, ÃÊ»ê Ä®·ý 60g,ÀÇ ¿ë¾×¿¡ 14Àϰ£ °íÁ¤ÇÑ´Ù. Ç¥º»ÀÇ »öÁ¶¸¦ Àç»ý½Ã۱â À§ÇÏ¿© 10-60ºÐ°£ 80% ¿¡Æ¿ ¾ËÄڿÿ¡ ´ã±Ù´Ù. º¸Á¸ ¾×¿¡´Â ±Û¸®¼¼¸° 500cc, 1% ¾Æºñ»ê 200cc, ¹° 2300cc, ÃÊ»ê Ä®·ý 250g, Ƽ¸ô 2.5g¸¦ È¥ÇÕÇÑ´Ù
  • label method
    øÆ÷ ¹æ¹ý
    µ¿ÀǾî=
  • Laewen's method
    ·¹º¥ ¹ý
    ½½ °üÀý Ãà³óÁõÀÇ ¹è³ó ¿ä¹ý.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
hamartoma syndrome, multiple A hereditary disease characterised by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Papules of the face and oral mucosa are the most characteristic lesion. Other changes occur in the skin, in the thyroid, the breast, the gastrointestinal system, and the nervous system.
(12 Dec 1998)
pregnancy, multiple The condition of bearing two or more foetuses simultaneously.
(12 Dec 1998)
hereditary multiple exostoses A disturbance of enchondral bone growth in which multiple, generally benign osteochondromas of long bones appear during childhood, commonly with shortening of the radius and fibula; the ill-effects are usually mechanical but malignant change is rare; autosomal dominant inheritance.
Synonym: diaphysial aclasis, hereditary deforming chondrodystrophy, multiple exostosis, osteochondromatosis.
(05 Mar 2000)
hereditary multiple trichoepithelioma <tumour> Multiple small benign nodules, occurring mostly on the skin of the face, derived from basal cells of hair follicles enclosing small keratin cysts; frequent autosomal dominant inheritance.
Synonym: acanthoma adenoides cysticum, Brooke's tumour, epithelioma adenoides cysticum, hereditary multiple trichoepithelioma.
Origin: tricho-+ epithelioma
(05 Mar 2000)
sclerosis, multiple The National Multiple Sclerosis Society says of ms that it is a disease that randomly attacks your central nervous system, wearing away the control you have over your body. Symptoms may range from numbness to paralysis and blindness. The progress, severity and specific symptoms cannot be foreseen. You never know when attacks will occur, how long they will last, or how severe they will be. most people are diagnosed with ms between the ages of 20 and 40. In medical terms, ms involves demyelinization of the white matter sometimes extending into the gray matter. Demyelinization is loss of myelin, the coating of nerve fibres composed of lipids (fats) and protein that serves as insulation and permits efficient nerve fibre conduction. The white matter is the part of the brain which contains myelinated nerve fibres and appears white, whereas the gray matter is the cortex of the brain which contains nerve cell bodies and appears gray. When myelin is damaged in ms, nerve fibre conduction is faulty or absent. Impaired bodily functions or altered sensations associated with those demyelinated nerve fibres give rise to the symptoms of ms. Recent research (1998) has also identified nerve cell death as part of the nervous system injury in ms.
(12 Dec 1998)
psychotherapy, multiple The use of more than one therapist at one time in individual or group psychotherapy.
(12 Dec 1998)
neoplasms, multiple primary Two or more abnormal growths of tissue occurring simultaneously. The neoplasms are histologically different and may be found in the same or different sites.
(12 Dec 1998)
drug resistance, multiple Simultaneous resistance to a broad spectrum of structurally and functionally distinct drugs following exposure to a single agent. It is thought to result from the overexpression of genes encoding an integral plasma membrane protein, p-glycoprotein.
(12 Dec 1998)
exostoses, multiple hereditary Hereditary disorder transmitted by an autosomal dominant gene and characterised by multiple exostoses (multiple osteochondromas) near the ends of long bones. The genetic abnormality results in a defect in the osteoclastic activity at the metaphyseal ends of the bone during the remodeling process in childhood or early adolescence. The metaphyses develop benign, bony outgrowths often capped by cartilage. A small number undergo neoplastic transformation.
(12 Dec 1998)
familial multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
law of multiple proportions The relative weights in which two substances form a chemical union singly with a third are the same as, or simple multiples of, those in which they unite with each other; a corollary of the law of definite proportions.
Synonym: law of multiple proportions.
(05 Mar 2000)
lipomatosis, multiple symmetrical Multiple circumscribed or encapsulated lipomas which may be distributed symmetrically or haphazardly or which may form a collar around the neck.
(12 Dec 1998)
Abbott's method A method of treatment of scoliosis by use of a series of plaster jackets applied after partial correction of the curvature by external force.
(05 Mar 2000)
Abell-Kendall method A standard method for estimation of total serum cholesterol involving saponification of cholesterol ester by hydroxide, extraction with petroleum ether, and colour development with acetic anhydride-sulfuric acid; the method avoids interference by bilirubin, protein, and haemoglobin.
(05 Mar 2000)
activated sludge method A method of sewage disposal in which the sewage is treated with 15% bacterially active, liquid sludge, which is produced by repeated vigorous aeration of fresh sewage to form floccules or sediment; when this flocculation process is complete, the resulting activated sludge contains large numbers of bacteria, together with yeasts, molds, and protozoa, which actively effect the oxidation of organic compounds; this mixture is piped to a sedimentation tank, the effluent from which is completely treated sewage.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á